Christian Reichen, PhD

Director, Oncology Research at Molecular Partners AG

Speaker

Christian Reichen - Director & Project Leader at Molecular Partners - leads research programs at Molecular Partners focused on developing DARPin-based radiopharmaceuticals for targeted cancer therapy. Under his leadership, several molecules have advanced into clinical development, including MP0712, the first DLL3-targeting Radio-DARPin candidate for small cell lung cancer (SCLC), and MP0533, a DARPin-based T-cell engager currently in trials for acute myeloid leukemia (AML).Earlier in his career at Molecular Partners, Christian contributed to multiple pipeline projects through protein engineering and sequence optimization. He earned his Ph.D. at the University of Zurich in the laboratory of Prof. Andreas Plückthun, where he developed a novel binding scaffold based on armadillo repeat proteins using computational design. He holds a master's degree from ETH Zurich.